Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]

Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]

In the debate over prescription drug pricing, some pharmaceutical industry critics claim that U.S. taxpayers pay twice for costly therapies, because publicly supported research is a major contributor to drug discovery and American taxpayers are inadequately rewarded for their research investment due...

Full description

Bibliographic Details
Main Authors: Rena M. Conti, Frank S. David
Format: Article
Language:English
Published: F1000 Research Ltd 2020-07-01
Series:F1000Research
Online Access:https://f1000research.com/articles/9-707/v1
id doaj-2aeb9b72d5f340bd871b2230320a8c9c
record_format Article
spelling doaj-2aeb9b72d5f340bd871b2230320a8c9c2020-11-25T03:58:14ZengF1000 Research LtdF1000Research2046-14022020-07-01910.12688/f1000research.24934.127509Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]Rena M. Conti0Frank S. David1Questrom School of Business, Boston University, Boston, MA, 02215, USAPharmagellan LLC, Milton, MA, 02186, USAIn the debate over prescription drug pricing, some pharmaceutical industry critics claim that U.S. taxpayers pay twice for costly therapies, because publicly supported research is a major contributor to drug discovery and American taxpayers are inadequately rewarded for their research investment due to high drug prices. In fact, the empirical evidence supporting these claims is weak, and the pay twice argument distracts from important efforts to ensure that impactful new drugs continue to be developed and made widely available to patients who need them.https://f1000research.com/articles/9-707/v1
collection DOAJ
language English
format Article
sources DOAJ
author Rena M. Conti
Frank S. David
spellingShingle Rena M. Conti
Frank S. David
Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
F1000Research
author_facet Rena M. Conti
Frank S. David
author_sort Rena M. Conti
title Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
title_short Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
title_full Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
title_fullStr Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
title_full_unstemmed Public research funding and pharmaceutical prices: do Americans pay twice for drugs? [version 1; peer review: 2 approved]
title_sort public research funding and pharmaceutical prices: do americans pay twice for drugs? [version 1; peer review: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2020-07-01
description In the debate over prescription drug pricing, some pharmaceutical industry critics claim that U.S. taxpayers pay twice for costly therapies, because publicly supported research is a major contributor to drug discovery and American taxpayers are inadequately rewarded for their research investment due to high drug prices. In fact, the empirical evidence supporting these claims is weak, and the pay twice argument distracts from important efforts to ensure that impactful new drugs continue to be developed and made widely available to patients who need them.
url https://f1000research.com/articles/9-707/v1
work_keys_str_mv AT renamconti publicresearchfundingandpharmaceuticalpricesdoamericanspaytwicefordrugsversion1peerreview2approved
AT franksdavid publicresearchfundingandpharmaceuticalpricesdoamericanspaytwicefordrugsversion1peerreview2approved
_version_ 1724458452975091712

Similar Items